Literature DB >> 24402942

Climbing RAS, the everest of oncogenes.

Mariangela Russo1, Federica Di Nicolantonio, Alberto Bardelli.   

Abstract

SUMMARY: Mutations that activate the small GTP-binding protein KRAS are the most common oncogenic event in human tumors. Thirty years after its discovery, mutant KRAS has yet to be therapeutically conquered.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24402942     DOI： 10.1158/2159-8290.CD-13-0906

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  13 in total

1.  A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers.

Authors:  Suman Rao; Guangyan Du; Marc Hafner; Kartik Subramanian; Peter K Sorger; Nathanael S Gray
Journal:  J Biol Chem       Date:  2019-03-11       Impact factor: 5.157

Review 2.  National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.

Authors:  Thomas J George; Aaron J Franke; A Bapsi Chakravarthy; Prajnan Das; Arvind Dasari; Bassel F El-Rayes; Theodore S Hong; Timothy J Kinsella; Jerome C Landry; James J Lee; Arta M Monjazeb; Samuel A Jacobs; David Raben; Osama E Rahma; Terence M Williams; Christina Wu; C Norman Coleman; Bhadrasain Vikram; Mansoor M Ahmed
Journal:  Cancer       Date:  2019-04-24       Impact factor: 6.860

3.  Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.

Authors:  Lihong Wang-Bishop; Zheng Chen; Ahmed Gomaa; Albert Craig Lockhart; Safia Salaria; Jialiang Wang; Keeli B Lewis; Jeffrey Ecsedy; Kay Washington; Robert Daniel Beauchamp; Wael El-Rifai
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 22.682

Review 4.  Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.

Authors:  Marco H Hofmann; Daniel Gerlach; Sandra Misale; Mark Petronczki; Norbert Kraut
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

5.  Crystalline silica-induced leukotriene B4-dependent inflammation promotes lung tumour growth.

Authors:  Shuchismita R Satpathy; Venkatakrishna R Jala; Sobha R Bodduluri; Elangovan Krishnan; Bindu Hegde; Gary W Hoyle; Mostafa Fraig; Andrew D Luster; Bodduluri Haribabu
Journal:  Nat Commun       Date:  2015-04-29       Impact factor: 14.919

6.  Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides.

Authors:  Thi B Trinh; Punit Upadhyaya; Ziqing Qian; Dehua Pei
Journal:  ACS Comb Sci       Date:  2015-12-23       Impact factor: 3.784

Review 7.  Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.

Authors:  Hidenori Kitai; Hiromichi Ebi
Journal:  Small GTPases       Date:  2016-07-08

Review 8.  Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes.

Authors:  Federica Gaiani; Federica Marchesi; Francesca Negri; Luana Greco; Alberto Malesci; Gian Luigi de'Angelis; Luigi Laghi
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

9.  Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.

Authors:  Jieqiong Wang; Kewen Hu; Jiawei Guo; Feixiong Cheng; Jing Lv; Wenhao Jiang; Weiqiang Lu; Jinsong Liu; Xiufeng Pang; Mingyao Liu
Journal:  Nat Commun       Date:  2016-05-19       Impact factor: 14.919

10.  Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain.

Authors:  Irena Antic; Marco Biancucci; Yueming Zhu; David R Gius; Karla J F Satchell
Journal:  Nat Commun       Date:  2015-06-08       Impact factor: 17.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.